Keeping Track: Sanofi Submits Lixisenatide NDA (Again); Sandoz Files Second Biosimilar Application
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
The latest application submission news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Decision to price combo of Yervoy and Opdivo at just 6% more than Yervoy monotherapy could set a trend for the market.
ELIXA trial results show neither increased nor decreased risk of major adverse cardiovascular events; Sanofi's diabetes drug, still unapproved in the U.S., becomes the only GLP-1 receptor agonist with CV outcomes data.